Kwality Pharmaceuticals Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Kwality Pharmaceuticals Ltd trades at ₹2,393, in a confirmed uptrend and 24 weeks into that stage. That is +75.1% against its own 200-day average. It sits at 100% of a 52-week range of ₹718 to ₹2,393. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 20 straight weeks.

Today the stock is in a confirmed uptrend — week 24 of stage 2, confirmed. At ₹2,393 it trades +75.1% versus its 200-day average and sits at 100% of its 52-week range (₹718–₹2,393).

Against the market, two honest reads. Cumulative: over the last 9.9 years the stock moved +10,537% while the NIFTY 500 moved +208% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 20 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Kwality Pharmaceuticals Ltd's story is not scored yet against the markers our research file set on 17 May 2026. Where it sits in its own cycle: FULLY_EXPANDED. Still open: Revenue miss (₹124 vs ₹140 Cr), Unit 6 CWIP=0 contradiction, US market strategic pivot, Africa subsidiary exit — all surfaced in a single Feb 2026 concall.

Our read, 17 May 2026. A commodity-generics formulator mid-leap into regulated-market exports and biologics — 4-quarter momentum validates the move; management credibility under watch.

From the numbers. PE at 82nd percentile (1.9× median), segment FULLY_EXPANDED — the market has already priced in significant execution. Unlike RRKABEL where PE compression was earnings-driven, KPL's PE expansion is multiple-expansion…

From the price. Price stage 2, week 24 — above its 200-day line, relative strength rising.

From the research. A commodity-generics formulator mid-leap into regulated-market exports and biologics — 4-quarter momentum validates the move; management credibility under watch.

🚨 Where they disagree. PE at 82nd percentile (1.9× median), segment FULLY_EXPANDED — the market has already priced in significant execution. Unlike RRKABEL where PE compression was earnings-driven, KPL's PE expansion is multiple-expansion (price running ahead of a short 4Q track record). The cycle history shows prior peaks at PE 26 (Jun 2017) and 9.7 (Jun 2021) — both followed by sharp contractions. The current reading at 24.45 is approaching the 2017 peak level. EPS trajectory is the positive counter: ₹11.50 → ₹13.61 → ₹15.43 across Q1-Q3 FY26.

What is proven. A commodity-generics formulator mid-leap into regulated-market exports and biologics — 4-quarter momentum validates the move; management credibility under watch.

What is not proven yet. Revenue miss (₹124 vs ₹140 Cr), Unit 6 CWIP=0 contradiction, US market strategic pivot, Africa subsidiary exit — all surfaced in a single Feb 2026 concall.

The test written in advance. Management credibility — 4 documented consistency failures — Management credibility — 4 documented consistency failures Q1 FY27 revenue vs ₹140-150 Cr target; Unit 5 hormone plant CWIP in balance sheet by the next result.

The test written in advance. PE at 82nd percentile — re-rating risk on any guidance miss — PE at 82nd percentile — re-rating risk on any guidance miss Q1 FY27 revenue trajectory; OPM vs 24% Dec quarter benchmark by the next result.

The test written in advance. Biologic execution — first-time EPO launch risk — Biologic execution — first-time EPO launch risk Clinical trial commencement April 2027; interim export announcement H1 FY27 by the next result.

What the company does. Revenue accelerated 4 consecutive quarters (YoY: +26%, +39%, +23%, +46%), OPM expanded from 21% to 24%, TTM PAT +93% — the inflection is real. Management's FY27 PAT target of ₹100 Cr (vs TTM ~₹56 Cr) is bold; Erythropoietin biologic launch and Mexico/Colombia registrations are the next proof points. PE at 82nd percentile (1.9× median) prices in significant execution — four documented consistency failures (revenue miss, CWIP contradiction, US pivot, Africa exit) make management the key monitorable.

Lever 1 · Operating leverage — BUILDING. Revenue +26/39/23/46% YoY over 4 quarters; OPM 21→22→23→24% — operating leverage converting revenue growth to PAT +93% TTM. What proves it keeps working: Operating Leverage Inflection. It stops working if Q1 FY27 revenue vs ₹140-150 Cr target; Unit 5 hormone plant CWIP in balance sheet.

Lever 5 · Regulatory approval — BUILDING. First biologic launch — EPO pre-clinical approved, clinical trials April 2027, interim export H1 FY27; biologic mix structurally expands OPM to 29-30% by FY29. What proves it keeps working: Biologic Launch — Erythropoietin (EPO). It stops working if Q1 FY27 revenue vs ₹140-150 Cr target; Unit 5 hormone plant CWIP in balance sheet.

Lever 10 · New geographies — BUILDING. Mexico/Colombia/Algeria registrations moving to commercialization — management guides ₹200 Cr incremental FY27 from these 3 markets alone (vs H1 FY26 baseline of ₹60-70 Cr from all 3 combined). What proves it keeps working: Geographical Expansion — Regulated Markets (Mexico, Colombia, Algeria). It stops working if Q1 FY27 revenue vs ₹140-150 Cr target; Unit 5 hormone plant CWIP in balance sheet.

Lever 7 · Consolidation — BUILDING. CCC target 170-180 days from ~280 days — inventory optimization and mix shift to higher-paying markets (Mexico/Colombia) releasing capital; ROCE trajectory improving. What proves it keeps working: Working Capital Normalization. It stops working if Q1 FY27 revenue vs ₹140-150 Cr target; Unit 5 hormone plant CWIP in balance sheet.

Sources: our stock research file (17 May 2026) · quarterly results through Mar 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Kwality Pharmaceuticals Ltd reported ₹157 Cr of revenue in the Mar 26 quarter, +35.3% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 21.1% a year. The last full year, FY26, came in at ₹503 Cr. The last four reported quarters add to ₹502 Cr.

Why this happened. The near-term revenue driver. Regulated export markets carry 2-3× the realization of domestic generics. Management's H1 FY26 baseline is ₹60-70 Cr from these three markets; the FY27 guide is ₹200 Cr incremental (implying ₹260-270 Cr from these markets alone in FY27). The 40+ bioequivalence programs and 400-500 out-licensed molecules across 30-40 countries build the long-term distribution moat. The short-term proof point is whether Q1 FY27 revenue shows the ₹50 Cr+ run-rate from these geographies.

FY26 revenue came in at ₹503 Cr (+35.9% on the year), capping 10 years at 21.1% compound. The latest quarter (Mar 26) printed ₹157 Cr, +35.3% year on year — the 11th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +35.9% growth against the decade's 21.1% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +35.7% over the last 4 quarters against +27.9%/yr over the last 8 — accelerating; TTM profit +71.8% vs +70.7%/yr — stabilising.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Kwality Pharmaceuticals Ltd's operating margin is 25.0% in the Mar 26 quarter, +3.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0% to 38.0%. The current quarter sits inside that band.

Why this happened. The core driver. Kwality's move to regulated markets (EU-GMP, PIC/S certified) unlocks higher pricing on the same manufacturing base. The OPM expansion from 21% to 24% reflects both mix shift (regulated export premium) and operating leverage on fixed cost. The FY27 guide of 25-26% EBITDA implies another 100-200bps of expansion — supported by biosimilar/biologic mix shift, which carries structurally higher margins than commodity generics. The revenue trajectory is the cleanest signal: 4 consecutive acceleration quarters, with Dec 2025 quarter at ₹123 Cr vs Dec 2024 ₹84 Cr (+46.4% YoY).

The latest quarter's operating margin is 25.0%, +3.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0%–38.0%.

Why the margin moved: operating margin went +2.3 pp year on year while gross margin went −2.6 pp — the gain came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Kwality Pharmaceuticals Ltd earned ₹25.0 Cr of net profit in the Mar 26 quarter, +78.6% year on year. It is the 8th consecutive quarter of growth. Full-year FY26 profit was ₹67.0 Cr. The 10-year compound rate is 52.3%. That is 15.9% of the quarter's revenue. The same quarter a year earlier earned ₹14.0 Cr.

Mar 26 profit was ₹25.0 Cr, +78.6% year on year — the 8th consecutive quarter of growth. On the full year, FY26 printed ₹67.0 Cr (+67.5%), and the 10-year compound rate is 52.3%.

Why profit moved: revenue contributed +35.3% and the margin +3.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +70.3% vs revenue +35.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 86% of Kwality Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹17.0 Cr of operating cash against ₹67.0 Cr of profit. After ₹47.0 Cr of capital spending, ₹−30.0 Cr was left as free cash.

FY26: operating cash of ₹17.0 Cr against reported profit of ₹67.0 Cr, leaving free cash of ₹−30.0 Cr after ₹47.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 86% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 86%: the cash cycle stretched 140 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 1.7× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Kwality Pharmaceuticals Ltd's cash conversion cycle runs 170 days in FY26, up from 30 days in FY21. Capital spending ran ₹97.0 Cr over the last 3 years. At FY26 sales of ₹503 Cr each day of that cycle holds about ₹1.4 Cr, so roughly ₹234 Cr sits inside the business at any moment.

FY26: debtors at 203 days, inventory at 111 days — roughly 3.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 170 days, looser than FY21's 30.

The full loop: cash goes out to suppliers and production on day 0; stock waits 111 days to sell; customers pay about 203 days after that; and suppliers themselves are paid at 144 days — netting out to the 170-day cycle.

In money terms: at FY26 sales of ₹503 Cr, each day of the cycle holds about ₹1.4 Cr — so the 170-day loop keeps roughly ₹234 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹97.0 Cr over the last 3 fiscal years against ₹58.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹17.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Kwality Pharmaceuticals Ltd earns a ROCE of 24% in FY26. That is up from a trough of 9% in FY15. Return on invested capital clears the cost of that capital by +7.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 13.3% net margin on 0.85× asset turns.

FY26 ROCE is 24%, recovered from a FY15 trough of 9% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 13.3% net margin × 0.85× asset turns × 1.79× balance-sheet leverage ≈ 20.2% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 19.5% − 12.0% = a +7.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Kwality Pharmaceuticals Ltd carries total debt of ₹130 Cr against shareholder equity of ₹330 Cr as of Mar 26, a debt-to-equity of 0.39. On the annual view that ratio went from 0.35 in FY22 to 0.39 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹130 Cr against shareholder equity of ₹330 Cr — a debt-to-equity of 0.39. On the annual view, debt-to-equity went from 0.35 (FY22) to 0.39 (FY26). Read the returns on this page with that leverage in mind.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions added 2.8 points of Kwality Pharmaceuticals Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 2.8% of the company. Domestic institutions moved +0.4 points over the same window, to 0.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +2.8 points over 8 quarters to 2.8%; Domestic institutions: +0.4 points over 8 quarters to 0.4%; Promoters: +0.0 points over 8 quarters to 54.9%.

Why the register moved: foreign institutions drove it (+2.8 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Kwality Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

Why this happened. The strategic step-change catalyst. EPO (Erythropoietin) is the company's first biosimilar, with a clear regulatory pathway: interim export beginning June-July 2027, India commercialization August 2027. Management's guide to 40+ bioequivalence programs and five CDMO partnerships with European innovators creates a pipeline overlay. The biologic thesis is incremental margin, not incremental volume — a single biologic molecule in the oncology/biosimilar segment can contribute at 35-40% gross margin vs the 24% current blended OPM. This is the driver underpinning the FY29 margin guide of 29-30%. Risk: first-time biologics execution, regulatory approval uncertainty, clinical trial timeline.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Kwality Pharmaceuticals Ltd trades at 36.6× P/E, about the priciest it has ever traded. Its long-run median P/E is 14.5×, measured across 9.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 36.6× is about the priciest it has ever traded, against a long-run median of 14.5× measured over 9.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

🚨 Why the multiple sits where it does: over the past year annual EPS moved +69.0% against a +158.2% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the +87.1%/yr price move, ~+43.9%/yr came from earnings growth and ~+43.2 pp from the multiple (expanding); over 10y, of the +59.5%/yr price move, ~+53.5%/yr came from earnings growth and ~+6.0 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Kwality Pharmaceuticals Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 31.1% and holding. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

4-Factor Sector Score

No sector-relative score — Kwality Pharmaceuticals Ltd is not present in the sector comparison for Pharma - Formulators.

The score is a rank WITHIN a peer set: every metric is scored by percentile against the other members. Without the peer set there is no score to state, so none is invented here.

Said versus delivered

What Kwality Pharmaceuticals Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

🚨 Revenue Target Execution Failure · 13 February 2026. Management previously established a quarterly revenue target of 140 crores, but the February 2026 call reports a failed execution with results closing at 124 crores. While management now claims guidance will be achieved 'irrespective of external factors,' they inconsistentally blame the 11% revenue miss on the Christmas holiday period. Later call (Feb 2026): “Preeti Agarwal noted we missed a previous 140 crore topline forecast; what were the reasons?” Later call (Feb 2026): “We missed the 140 crore quarterly target due to Christmas holidays... so we closed at 124 crores.”

Unit 6 Progress and Balance Sheet Contradiction · 13 February 2026. Management asserts that construction for the Unit 6 hormone plant restarted in FY26 following a pause. However, this is contradicted by the H1 FY26 balance sheet which shows zero Capital Work-in-Progress (CWIP), an inconsistency that suggests no actual investment or construction occurred during that period despite claims of a restart. Later call (Feb 2026): “Hormone expansion actually started in FY26. Initial work was paused due to cash flow constraints. As cash flows improved this past year, we restarted.” Later call (Feb 2026): “Regarding Unit 6, Mr. Abhijit noted that work started in FY24, but the H1 FY26 balance sheet shows zero Capital Work-in-Progress (CWIP).”

US Market Strategic Reversal · 13 February 2026. Management has fundamentally changed their approach to the U.S. market, admitting that their previous long-standing strategy was 'incorrect.' The focus has shifted from standard human pharmaceutical entry to pursuing a veterinary drug ANDA in FY27, representing a significant pivot in regulatory and commercial focus. Later call (Feb 2026): “Our previous approach to the US market was incorrect. In the last year, we partnered with a US firm to shift molecules to our cephalosporin and beta-lactam lines.” Later call (Feb 2026): “We expect to make an ANDA application in Q1 or Q2 of FY27. This will likely be for a veterinary drug.”

Abandonment of African Subsidiary Strategy · 13 February 2026. The company has reversed its strategy for geographic expansion through its African subsidiary, which was originally intended to capture Mozambique government tenders. In the February 2026 call, management confirms they are curtailing this business and plan to close the entity entirely due to payment delays. Later call (Feb 2026): “Regarding the African subsidiary, it was for Mozambique tenders, but we have curtailed that business due to payment delays.” Later call (Feb 2026): “We might close that entity in the next year or two.”

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions